

of applicant's claimed invention. No new matter has been entered into the application through the foregoing amendments. Reconsideration of remaining Claims 5-13 is requested in view of the foregoing amendments and following comments.

Rejection of Claims Under 35 U.S.C. § 112


The Examiner has rejected Claims 1-13 under 35 U.S.C. § 112, second paragraph, as being indefinite in the definition for R₂, the recitation of "and the pharmaceutically acceptable salts" and the use of the word "enhance". This rejection is believed to be moot in view of the foregoing claim amendments.

Rejection of Claims Under 35 U.S.C. § 102

The Examiner has rejected Claims 1-4 under 35 U.S.C. § 102(b) as being anticipated by U.S. Patent Nos. 5,321,128, 5,422,368, and 5,462,369 [sic, believed to be 5,422,369]. Without acquiescence in the Examiner's rejection of these claims or prejudice to applicant's right to pursue the subject matter of these claims in a separate application, Claims 1-4 have been cancelled from the application in order to narrow the issues and advance prosecution of the present application.

Other Matters

The Examiner's attention is directed to reference O22 as cited in applicant's previously filed Information Disclosure Statement. Reference O22 was cited by the U.S. Preliminary Examining Authority in applicant's parent international application PCT/US98/02289 as being material to the patentability of applicant's original claims in that application. Reference O22 is an English language abstract of Daichi Seiyaku Co. Japanese patent publication Serial No. 61-218510(A) [reference F2] that the Examiner has crossed off of applicant's listing of cited references.



LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

The abstract (O22) discloses cosmetics containing prostaglandin E1 (PGE1) and/or prostaglandin I2 (PGI2) and indicates an observation of hair growth after application for two months.


As amended above, applicant's claims have been limited to the application of prostaglandin PGF compounds of a structurally defined class. There is no disclosure or remote suggestion of the methods of applicant's amended claims in the abstract (O22), and applicant's amended claims are believed to be clearly patentable thereover.

CONCLUSION

Amended Claims 5-13 are believed to be in condition for allowance. Reconsideration and favorable action is requested.

Respectfully submitted,

CHRISTENSEN O'CONNOR
JOHNSON KINDNESS^{PLLC}


Dennis K. Shelton
Registration No. 26,997
Direct Dial No. 206.695.1718

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid and addressed to the Commissioner for Patents, Washington, D.C. 20231, on the below date.

Date:

January 3, 2001

Carole Julian

DKS:cj

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

